vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and ARGENX SE (ARGX). Click either name above to swap in a different company.
ARGENX SE is the larger business by last-quarter revenue ($2.5B vs $169.0K, roughly 14636.1× Aligos Therapeutics, Inc.). ARGENX SE runs the higher net margin — 35.5% vs -11763.9%, a 11799.4% gap on every dollar of revenue. On growth, ARGENX SE posted the faster year-over-year revenue change (83.2% vs -72.1%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
ALGS vs ARGX — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $2.5B |
| Net Profit | $-19.9M | $877.2M |
| Gross Margin | — | 89.5% |
| Operating Margin | -12907.7% | 28.9% |
| Net Margin | -11763.9% | 35.5% |
| Revenue YoY | -72.1% | 83.2% |
| Net Profit YoY | 75.8% | 1.3% |
| EPS (diluted) | $4.23 | $13.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | $2.5B | ||
| Q3 25 | $741.0K | — | ||
| Q2 25 | $965.0K | $1.8B | ||
| Q1 25 | $311.0K | — | ||
| Q4 24 | $606.0K | $1.4B | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $1.1M | $901.9M | ||
| Q1 24 | $694.0K | — |
| Q4 25 | $-19.9M | $877.2M | ||
| Q3 25 | $-31.5M | — | ||
| Q2 25 | $-15.9M | $414.8M | ||
| Q1 25 | $43.1M | — | ||
| Q4 24 | $-82.2M | $865.6M | ||
| Q3 24 | $-19.3M | — | ||
| Q2 24 | $5.1M | $-32.5M | ||
| Q1 24 | $-34.9M | — |
| Q4 25 | — | 89.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 89.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 90.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 89.4% | ||
| Q1 24 | — | — |
| Q4 25 | -12907.7% | 28.9% | ||
| Q3 25 | -3827.4% | — | ||
| Q2 25 | -1924.0% | 19.2% | ||
| Q1 25 | -6187.5% | — | ||
| Q4 24 | -3393.2% | 8.7% | ||
| Q3 24 | -1610.5% | — | ||
| Q2 24 | -2489.5% | -15.4% | ||
| Q1 24 | -3176.7% | — |
| Q4 25 | -11763.9% | 35.5% | ||
| Q3 25 | -4256.0% | — | ||
| Q2 25 | -1643.8% | 23.4% | ||
| Q1 25 | 13854.7% | — | ||
| Q4 24 | -13556.1% | 64.1% | ||
| Q3 24 | -1540.7% | — | ||
| Q2 24 | 477.0% | -3.6% | ||
| Q1 24 | -5023.5% | — |
| Q4 25 | $4.23 | $13.25 | ||
| Q3 25 | $-3.04 | — | ||
| Q2 25 | $-1.53 | $6.32 | ||
| Q1 25 | $-2.11 | — | ||
| Q4 24 | $-13.10 | $13.33 | ||
| Q3 24 | $-3.07 | — | ||
| Q2 24 | $0.81 | $-0.55 | ||
| Q1 24 | $-5.58 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $3.5B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $7.3B |
| Total Assets | $88.5M | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | $3.5B | ||
| Q3 25 | $99.1M | — | ||
| Q2 25 | $122.9M | $2.1B | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $56.9M | $1.5B | ||
| Q3 24 | $74.9M | — | ||
| Q2 24 | $94.5M | $1.4B | ||
| Q1 24 | $112.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $11.0M | ||
| Q1 24 | — | — |
| Q4 25 | $53.5M | $7.3B | ||
| Q3 25 | $71.8M | — | ||
| Q2 25 | $101.9M | $6.1B | ||
| Q1 25 | $116.4M | — | ||
| Q4 24 | $-29.0M | $5.5B | ||
| Q3 24 | $50.1M | — | ||
| Q2 24 | $67.2M | $4.3B | ||
| Q1 24 | $59.8M | — |
| Q4 25 | $88.5M | $8.7B | ||
| Q3 25 | $109.8M | — | ||
| Q2 25 | $134.7M | $7.2B | ||
| Q1 25 | $150.7M | — | ||
| Q4 24 | $70.1M | $6.2B | ||
| Q3 24 | $88.4M | — | ||
| Q2 24 | $108.8M | $4.8B | ||
| Q1 24 | $127.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-21.7M | $323.3M |
| Free Cash FlowOCF − Capex | — | $322.4M |
| FCF MarginFCF / Revenue | — | 13.0% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 0.37× |
| TTM Free Cash FlowTrailing 4 quarters | — | $594.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-21.7M | $323.3M | ||
| Q3 25 | $-24.3M | — | ||
| Q2 25 | $-15.5M | $361.8M | ||
| Q1 25 | $-20.9M | — | ||
| Q4 24 | $-18.4M | $41.9M | ||
| Q3 24 | $-20.1M | — | ||
| Q2 24 | $-19.5M | $-124.7M | ||
| Q1 24 | $-22.7M | — |
| Q4 25 | — | $322.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $356.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $40.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-125.5M | ||
| Q1 24 | — | — |
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 20.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -13.9% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
